Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.2104640118 http://scihub22266oqcxt.onion/10.1073/pnas.2104640118 34408076!8536357!34408076     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2021 ; 118 (35): ä Nephropedia Template TP {{tp|p=34408076|t=2021. Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions |pdf=|usr=}}{{34408076}} gab.com Text Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=34408076 #FOAvip Slower than anticipated, COVID-19 vaccine production and distribution have impaired efforts to curtail the current pandemic. The standard administration schedule for most COVID-19 vaccines currently approved is two doses administered 3 to 4 wk apart. To increase the number of individuals with partial protection, some governments are considering delaying the second vaccine dose. However, the delay duration must take into account crucial factors, such as the degree of protection conferred by a single dose, the anticipated vaccine supply pipeline, and the potential emergence of more virulent COVID-19 variants. To help guide decision-making, we propose here an optimization model based on extended susceptible, exposed, infectious, and removed (SEIR) dynamics that determines the optimal delay duration between the first and second COVID-19 vaccine doses. The model assumes lenient social distancing and uses intensive care unit (ICU) admission as a key metric while selecting the optimal duration between doses vs. the standard 4-wk delay. While epistemic uncertainties apply to the interpretation of simulation outputs, we found that the delay is dependent on the vaccine mechanism of action and first-dose efficacy. For infection-blocking vaccines with first-dose efficacy >/=50%, the model predicts that the second dose can be delayed by >/=8 wk (half of the maximal delay), whereas for symptom-alleviating vaccines, the same delay is recommended only if the first-dose efficacy is >/=70%. Our model predicts that a 12-wk second-dose delay of an infection-blocking vaccine with a first-dose efficacy >/=70% could reduce ICU admissions by 400 people per million over 200 d. Twit Text FOAVip Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=34408076 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34408076 #FOAvip English Wikipedia <ref>{{Cite pmid|34408076}}</ref> Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions #MMPMID34408076 Silva PJS; Sagastizabal C; Nonato LG; Struchiner CJ; Pereira T Proc Natl Acad Sci U S A 2021[Aug]; 118 (35): ä PMID34408076show ga Slower than anticipated, COVID-19 vaccine production and distribution have impaired efforts to curtail the current pandemic. The standard administration schedule for most COVID-19 vaccines currently approved is two doses administered 3 to 4 wk apart. To increase the number of individuals with partial protection, some governments are considering delaying the second vaccine dose. However, the delay duration must take into account crucial factors, such as the degree of protection conferred by a single dose, the anticipated vaccine supply pipeline, and the potential emergence of more virulent COVID-19 variants. To help guide decision-making, we propose here an optimization model based on extended susceptible, exposed, infectious, and removed (SEIR) dynamics that determines the optimal delay duration between the first and second COVID-19 vaccine doses. The model assumes lenient social distancing and uses intensive care unit (ICU) admission as a key metric while selecting the optimal duration between doses vs. the standard 4-wk delay. While epistemic uncertainties apply to the interpretation of simulation outputs, we found that the delay is dependent on the vaccine mechanism of action and first-dose efficacy. For infection-blocking vaccines with first-dose efficacy >/=50%, the model predicts that the second dose can be delayed by >/=8 wk (half of the maximal delay), whereas for symptom-alleviating vaccines, the same delay is recommended only if the first-dose efficacy is >/=70%. Our model predicts that a 12-wk second-dose delay of an infection-blocking vaccine with a first-dose efficacy >/=70% could reduce ICU admissions by 400 people per million over 200 d. |Algorithms[MESH] |Brazil/epidemiology[MESH] |COVID-19 Vaccines/*administration & dosage/supply & distribution[MESH] |COVID-19/epidemiology/immunology/*prevention & control[MESH] |Hospitalization/*statistics & numerical data[MESH] |Humans[MESH] |Intensive Care Units/*statistics & numerical data[MESH] |SARS-CoV-2/*immunology[MESH] |Time-to-Treatment/*standards[MESH] |Treatment Outcome[MESH]Optimized delay of the second COVID-19 vaccine dose reduces ICU admiss(epmc).pdf DeepDyve Pubget Overpricing